Avadel Pharmaceuticals Net Worth
Avadel Pharmaceuticals Net Worth Breakdown | AVDL |
Avadel Pharmaceuticals Net Worth Analysis
Avadel Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Avadel Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Avadel Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Avadel Pharmaceuticals' net worth analysis. One common approach is to calculate Avadel Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Avadel Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Avadel Pharmaceuticals' net worth. This approach calculates the present value of Avadel Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Avadel Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Avadel Pharmaceuticals' net worth. This involves comparing Avadel Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Avadel Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Avadel Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Avadel Pharmaceuticals' net worth research are outlined below:
| The company reported the previous year's revenue of 169.12 M. Net Loss for the year was (48.83 M) with profit before overhead, payroll, taxes, and interest of 175.12 M. | |
| Avadel Pharmaceuticals PLC currently holds about 104.12 M in cash with (46.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74. | |
| Avadel Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 3500 shares by Palczuk Linda of Avadel Pharmaceuticals subject to Rule 16b-3 |
Avadel Pharmaceuticals Quarterly Good Will |
|
Avadel Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Avadel Pharmaceuticals PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Avadel Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Avadel Pharmaceuticals Target Price Consensus
Avadel target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Avadel Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Avadel analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Avadel stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Avadel Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAvadel Pharmaceuticals Target Price Projection
Avadel Pharmaceuticals' current and average target prices are 11.26 and 17.00, respectively. The current price of Avadel Pharmaceuticals is the price at which Avadel Pharmaceuticals PLC is currently trading. On the other hand, Avadel Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Avadel Pharmaceuticals Market Quote on 5th of August 2025
Target Price
Analyst Consensus On Avadel Pharmaceuticals Target Price
Know Avadel Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Avadel Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avadel Pharmaceuticals PLC backward and forwards among themselves. Avadel Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Avadel Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2025-03-31 | 1.7 M | Ubs Group Ag | 2025-03-31 | 1.3 M | Geode Capital Management, Llc | 2025-03-31 | 1.2 M | Bank Of America Corp | 2025-03-31 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1 M | Samsara Biocapital, Llc | 2025-03-31 | 967.5 K | Krensavage Asset Management, Llc | 2025-03-31 | 950 K | Woodline Partners Lp | 2025-03-31 | 896.9 K | Kennedy Capital Management Inc | 2025-03-31 | 754 K | Hhg Plc | 2025-03-31 | 13.6 M | Gendell Jeffrey L | 2025-03-31 | 6.1 M |
Follow Avadel Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.07 B.Market Cap |
|
Project Avadel Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.33) | (0.35) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.66) | (0.69) |
When accessing Avadel Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Avadel Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Avadel Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Avadel Pharmaceuticals' management efficiency
Avadel Pharmaceuticals has return on total asset (ROA) of (0.0721) % which means that it has lost $0.0721 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3465) %, meaning that it created substantial loss on money invested by shareholders. Avadel Pharmaceuticals' management efficiency ratios could be used to measure how well Avadel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.35. The value of Return On Capital Employed is expected to slide to -0.39. At this time, Avadel Pharmaceuticals' Non Current Assets Total are quite stable compared to the past year. Intangibles To Total Assets is expected to rise to 0.20 this year, although the value of Non Currrent Assets Other will most likely fall to about 7.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.78 | 0.74 | |
| Tangible Book Value Per Share | 0.60 | 0.57 | |
| Enterprise Value Over EBITDA | (26.72) | (25.38) | |
| Price Book Value Ratio | 13.54 | 14.22 | |
| Enterprise Value Multiple | (26.72) | (25.38) | |
| Price Fair Value | 13.54 | 14.22 | |
| Enterprise Value | 388.4 M | 201.8 M |
Management at Avadel Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 5.197 | Revenue | Quarterly Revenue Growth 0.932 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avadel Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avadel Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avadel Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avadel Pharmaceuticals Corporate Filings
F4 | 31st of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 29th of July 2025 Other Reports | ViewVerify | |
| 16th of July 2025 Other Reports | ViewVerify | |
| 14th of July 2025 Other Reports | ViewVerify |
Avadel Pharmaceuticals Earnings Estimation Breakdown
The calculation of Avadel Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Avadel Pharmaceuticals is estimated to be 0.06335 with the future projection ranging from a low of 0.0225 to a high of 0.1275. Please be aware that this consensus of annual earnings estimates for Avadel Pharmaceuticals PLC is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.02 Lowest | Expected EPS | 0.13 Highest |
Avadel Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Avadel Pharmaceuticals' value are higher than the current market price of the Avadel Pharmaceuticals stock. In this case, investors may conclude that Avadel Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Avadel Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 8 | 61.34% | 0.0 | 0.06335 | -0.26 |
Avadel Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Avadel Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Avadel Pharmaceuticals PLC predict the company's earnings will be in the future. The higher the earnings per share of Avadel Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Avadel Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Avadel Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Avadel Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Avadel Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Avadel Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-05-06 | 2025-03-31 | -0.07 | -0.05 | 0.02 | 28 | ||
2025-03-03 | 2024-12-31 | -0.02 | -0.05 | -0.03 | 150 | ||
2024-11-06 | 2024-09-30 | -0.05 | -0.0273 | 0.0227 | 45 | ||
2024-08-08 | 2024-06-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2024-05-08 | 2024-03-31 | -0.21 | -0.3 | -0.09 | 42 | ||
2024-02-29 | 2023-12-31 | -0.26 | -0.29 | -0.03 | 11 | ||
2023-11-08 | 2023-09-30 | -0.37 | -0.41 | -0.04 | 10 | ||
2023-08-09 | 2023-06-30 | -0.38 | -0.83 | -0.45 | 118 | ||
2023-05-04 | 2023-03-31 | -0.38 | -0.48 | -0.1 | 26 | ||
2023-03-29 | 2022-12-31 | -0.27 | -0.46 | -0.19 | 70 | ||
2022-11-09 | 2022-09-30 | -0.25 | -0.33 | -0.08 | 32 | ||
2022-08-09 | 2022-06-30 | -0.41 | -1.01 | -0.6 | 146 | ||
2022-05-09 | 2022-03-31 | -0.43 | -0.45 | -0.02 | 4 | ||
2022-03-17 | 2021-12-31 | -0.41 | -0.38 | 0.03 | 7 | ||
2021-11-08 | 2021-09-30 | -0.38 | -0.38 | 0.0 | 0 | ||
2021-08-09 | 2021-06-30 | -0.31 | -0.33 | -0.02 | 6 | ||
2021-05-10 | 2021-03-31 | -0.32 | -0.23 | 0.09 | 28 | ||
2021-03-09 | 2020-12-31 | -0.27 | -0.19 | 0.08 | 29 | ||
2020-11-09 | 2020-09-30 | -0.25 | -0.2 | 0.05 | 20 | ||
2020-08-10 | 2020-06-30 | -0.1 | -0.15 | -0.05 | 50 | ||
2020-05-11 | 2020-03-31 | -0.24 | -0.02 | 0.22 | 91 | ||
2020-03-12 | 2019-12-31 | -0.24 | -0.07 | 0.17 | 70 | ||
2019-11-12 | 2019-09-30 | -0.27 | -0.24 | 0.03 | 11 | ||
2019-08-09 | 2019-06-30 | -0.29 | -0.23 | 0.06 | 20 | ||
2019-05-08 | 2019-03-31 | -0.49 | -0.35 | 0.14 | 28 | ||
2019-03-15 | 2018-12-31 | -2.34 | 0.06 | 2.4 | 102 | ||
2018-11-05 | 2018-09-30 | -0.42 | -0.43 | -0.01 | 2 | ||
2018-08-07 | 2018-06-30 | -0.31 | -0.09 | 0.22 | 70 | ||
2018-05-02 | 2018-03-31 | -0.27 | -0.32 | -0.05 | 18 | ||
2018-03-08 | 2017-12-31 | -0.31 | -0.15 | 0.16 | 51 | ||
2017-11-08 | 2017-09-30 | -0.02 | 0.52 | 0.54 | 2700 | ||
2017-08-08 | 2017-06-30 | 0.04 | 0.68 | 0.64 | 1600 | ||
2017-05-09 | 2017-03-31 | -0.01 | 0.64 | 0.65 | 6500 | ||
2017-03-07 | 2016-12-31 | -0.29 | 0.26 | 0.55 | 189 | ||
2016-11-07 | 2016-09-30 | -0.23 | -0.54 | -0.31 | 134 | ||
2016-08-08 | 2016-06-30 | 0.06 | -0.48 | -0.54 | 900 | ||
2016-05-09 | 2016-03-31 | 0.14 | -0.15 | -0.29 | 207 | ||
2016-03-10 | 2015-12-31 | 0.09 | 1.75 | 1.66 | 1844 | ||
2015-11-12 | 2015-09-30 | 0.23 | -0.73 | -0.96 | 417 | ||
2015-07-30 | 2015-06-30 | 0.4 | -0.43 | -0.83 | 207 | ||
2015-05-15 | 2015-03-31 | 0.31 | 0.27 | -0.04 | 12 | ||
2015-03-19 | 2014-12-31 | -0.17 | -0.69 | -0.52 | 305 | ||
2014-10-31 | 2014-09-30 | -0.12 | -0.26 | -0.14 | 116 | ||
2014-07-29 | 2014-06-30 | -0.09 | -0.13 | -0.04 | 44 | ||
2014-05-12 | 2014-03-31 | -0.15 | -0.6 | -0.45 | 300 | ||
2014-03-06 | 2013-12-31 | -0.16 | 0.2 | 0.36 | 225 | ||
2013-10-31 | 2013-09-30 | -0.2 | -0.25 | -0.05 | 25 | ||
2013-07-29 | 2013-06-30 | -0.27 | -1.21 | -0.94 | 348 | ||
2013-05-07 | 2013-03-31 | -0.33 | -0.35 | -0.02 | 6 | ||
2013-02-28 | 2012-12-31 | -0.19 | 0.46 | 0.65 | 342 | ||
2012-11-05 | 2012-09-30 | -0.19 | -0.26 | -0.07 | 36 | ||
2012-07-25 | 2012-06-30 | -0.08 | 0.25 | 0.33 | 412 | ||
2012-05-07 | 2012-03-31 | -0.07 | -0.19 | -0.12 | 171 | ||
2012-03-14 | 2011-12-31 | 0.1 | -0.08 | -0.18 | 180 | ||
2011-11-02 | 2011-09-30 | -0.09 | 0.07 | 0.16 | 177 | ||
2011-07-25 | 2011-06-30 | -0.09 | -0.14 | -0.05 | 55 | ||
2011-05-09 | 2011-03-31 | -0.11 | -0.2 | -0.09 | 81 | ||
2011-03-03 | 2010-12-31 | 0.05 | 0.11 | 0.06 | 120 | ||
2010-07-28 | 2010-06-30 | -0.05 | -0.18 | -0.13 | 260 | ||
2010-05-05 | 2010-03-31 | -0.13 | -0.17 | -0.04 | 30 | ||
2010-03-08 | 2009-12-31 | -0.1 | -0.23 | -0.13 | 130 | ||
2009-11-16 | 2009-09-30 | -0.09 | -0.14 | -0.05 | 55 | ||
2009-08-05 | 2009-06-30 | -0.1 | -0.15 | -0.05 | 50 | ||
2009-05-11 | 2009-03-31 | -0.14 | 0.05 | 0.19 | 135 | ||
2009-03-04 | 2008-12-31 | -0.02 | -0.11 | -0.09 | 450 | ||
2008-11-03 | 2008-09-30 | -0.17 | -0.1 | 0.07 | 41 | ||
2008-08-06 | 2008-06-30 | -0.25 | -0.14 | 0.11 | 44 | ||
2008-05-13 | 2008-03-31 | -0.29 | -0.15 | 0.14 | 48 | ||
2008-03-03 | 2007-12-31 | -0.33 | -0.23 | 0.1 | 30 | ||
2007-10-30 | 2007-09-30 | -0.41 | -0.38 | 0.03 | 7 | ||
2007-08-01 | 2007-06-30 | -0.28 | -0.57 | -0.29 | 103 | ||
2007-05-07 | 2007-03-31 | -0.33 | -0.38 | -0.05 | 15 | ||
2007-03-07 | 2006-12-31 | -0.37 | -0.25 | 0.12 | 32 | ||
2006-11-01 | 2006-09-30 | -0.38 | -0.43 | -0.05 | 13 | ||
2006-07-31 | 2006-06-30 | -0.33 | -0.4 | -0.07 | 21 | ||
2006-05-03 | 2006-03-31 | -0.31 | -0.41 | -0.1 | 32 | ||
2006-03-07 | 2005-12-31 | -0.34 | -0.28 | 0.06 | 17 | ||
2005-10-26 | 2005-09-30 | -0.37 | -0.5 | -0.13 | 35 | ||
2005-07-27 | 2005-06-30 | -0.39 | -0.41 | -0.02 | 5 | ||
2005-05-05 | 2005-03-31 | -0.03 | 0.01 | 0.04 | 133 | ||
2005-03-11 | 2004-12-31 | 0.31 | 0.28 | -0.03 | 9 | ||
2004-10-28 | 2004-09-30 | 0.11 | 0.12 | 0.01 | 9 | ||
2004-07-29 | 2004-06-30 | 0.07 | -0.07 | -0.14 | 200 | ||
2004-04-29 | 2004-03-31 | 0.03 | 0.18 | 0.15 | 500 | ||
2004-03-11 | 2003-12-31 | 0.04 | 0.08 | 0.04 | 100 | ||
2003-10-30 | 2003-09-30 | 0.05 | -0.11 | -0.16 | 320 | ||
2003-07-30 | 2003-06-30 | 0.02 | -0.1 | -0.12 | 600 | ||
2003-04-30 | 2003-03-31 | 0.03 | -0.1 | -0.13 | 433 | ||
1999-02-23 | 1998-12-31 | -0.1 | -0.12 | -0.02 | 20 | ||
1998-10-27 | 1998-09-30 | -0.13 | -0.17 | -0.04 | 30 | ||
1998-07-31 | 1998-06-30 | -0.14 | -0.14 | 0.0 | 0 | ||
null | null | null | null | null | 0 | ||
1997-07-31 | 1997-06-30 | -0.24 | -0.22 | 0.02 | 8 | ||
1997-03-26 | 1996-12-31 | -0.18 | -0.15 | 0.03 | 16 |
Avadel Pharmaceuticals Corporate Management
| Gregory Davis | VP Development | Profile | |
| Richard Kim | Chief Officer | Profile | |
| Susan Rodriguez | Chief Officer | Profile | |
| Christian PharmD | Chief Affairs | Profile | |
| Jason Vaughn | Senior Operations | Profile | |
| Jennifer PharmD | Senior Affairs | Profile |
Already Invested in Avadel Pharmaceuticals PLC?
The danger of trading Avadel Pharmaceuticals PLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Avadel Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Avadel Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Avadel Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth 0.932 | Return On Assets | Return On Equity |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.